Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.

A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce prices. Here's what we know.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). Following President Trump’s comments last month on ...

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities. Learn why NVO stock is a buy.

Gordon Findlay is a Novo Nordisk manager based in Switzerland who didn’t attend the White House’s Nov. 6 drug pricing announcement. Robert F. Kennedy Jr. wasn’t fleeing the scene, a White House spokesperson wrote on X; he was seeking medical attention for the man who fainted.

Novo Nordisk today presented data at the 76th annual American Association for the Study of Liver Diseases (AASLD) meeting, The Liver Meeting® 2025, in Washington, D.C., evaluating the effects of semaglutide 2.

Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk's extraordinary shareholders' meeting scheduled for November 14.